ArticleInternational journal of molecular sciences2021
Characterization of an Endolysin Targeting
Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Microbiome-based therapeutics forGut microbes · 2026Review
- Isolation of phages infecting the zoonotic pathogenbioRxiv : the preprint server for biology · 2025Article
- Characterization of holins, the membrane proteins of coliphage ASEC2201: a genomewideFrontiers in microbiology · 2025Article
- Identification of cell wall binding domains and repeats inBiochemistry and biophysics reports · 2024Article
- Foodborne Clostridioides Species: Pathogenicity, Virulence and Biocontrol Options.Microorganisms · 2023Review
- Peptidoglycan Endopeptidase from Novel Adaiavirus Bacteriophage LysesMicroorganisms · 2023Article
- Insights into the Evolving Epidemiology ofAntibiotics (Basel, Switzerland) · 2023Review
- Assessing the Feasibility of Employing a Combination of a Bacteriophage-Derived Endolysin and Spore Germinants to Treat RelapsingMicroorganisms · 2023Article
- Emerging applications of phage therapy and fecal virome transplantation for treatment of Clostridioides difficile infection: challenges and perspectives.Gut pathogens · 2023Review
- The long and sinuous road to phage-based therapy ofFrontiers in medicine · 2023Review
- Biochemical Characterizations of the Putative Endolysin Ecd09610 Catalytic Domain fromAntibiotics (Basel, Switzerland) · 2022Article
- Potential Role of the Host-Derived Cell-Wall Binding Domain of Endolysin CD16/50L as a Molecular Anchor in Preservation of Uninfected Clostridioides difficile for New Rounds of Phage Infection.Microbiology spectrum · 2022Article
- Isolation and Characterization of a NovelViruses · 2022Article
- Phage therapy forFrontiers in immunology · 2022Review
- Battling Enteropathogenic Clostridia: Phage Therapy forFrontiers in microbiology · 2022Review
- Characterization and Genomic Analysis of a Novel Jumbo Bacteriophage vB_StaM_SA1 InfectingFrontiers in microbiology · 2022Article
- Article
- Endolysin, a Promising Solution against Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.